Основная статистика
| CIK | 1826457 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Monte Rosa Therapeutics, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commi |
|
| August 7, 2025 |
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates Phase 1 study of NEK7-directed molecular glue degrader (MGD) MRT-8102 underway, to investigate a potential novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome; initial readout anticipated in H1 2026 VAV1-directed MGD MRT-6160 advancing toward anticipated initiatio |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commis |
|
| May 8, 2025 |
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 study data demonstrate encouraging signals of clinical response in heavily pretreated castration-resistant pro |
|
| May 8, 2025 |
Proteome Editing Through Molecular Glue Degraders Innovating Beyond New Heights | May 2025 Proteome Editing Through Molecular Glue Degraders Innovating Beyond New Heights | May 2025 Forward-Looking Statements This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commissi |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc. |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 27, 2025 |
Monte Rosa Therapeutics, Inc. 321 Harrison Avenue, Suite 900 Boston, MA 02118 Monte Rosa Therapeutics, Inc. 321 Harrison Avenue, Suite 900 Boston, MA 02118 March 27, 2025 Via EDGAR Transmission Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes Re: Monte Rosa Therapeutics, Inc.: Registration Statement on Form S-3 filed March 20, 2025 (File No. 333-285942) Ladies and Gent |
|
| March 20, 2025 |
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine release from T and B cells following |
|
| March 20, 2025 |
As filed with the Securities and Exchange Commission on March 20, 2025 As filed with the Securities and Exchange Commission on March 20, 2025 Registration No. |
|
| March 20, 2025 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named Exhibit 4.6 MONTE ROSA THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’ |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40522 Monte Rosa Ther |
|
| March 20, 2025 |
Power of Attorney (included on the signature pages to the Registration Statement) S-3 Table of Contents As filed with the Securities and Exchange Commission on March 20, 2025 Registration No. |
|
| March 20, 2025 |
Insider Trading Policy and Rule 10b5-1 Trading Plan Policy MONTE ROSA THERAPEUTICS, INC. AMENDED AND RESTATED Insider Trading POLICY Monte Rosa Therapeutics, Inc. (the “Company”) has adopted the following policy and procedures for securities trading by Company directors and employees (our “Insider Trading Policy”). Our Insider Trading Policy is intended to prevent the misuse of material nonpublic information, insider trading in securities, and the severe |
|
| March 20, 2025 |
Exhibit 107 Calculation of Registration Fee Form S-8 (Form Type) Monte Rosa Therapeutics, Inc. |
|
| March 20, 2025 |
Monte Rosa Therapeutics, Inc. Amended and Restated Compensation Recovery Policy Monte Rosa Therapeutics, Inc. COMPENSATION RECOVERY POLICY Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in accordance |
|
| March 20, 2025 |
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commi |
|
| March 20, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Monte Rosa Therapeutics, Inc. |
|
| March 20, 2025 |
List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Registrant Subsidiary Jurisdiction of Incorporation or Organization Monte Rosa Therapeutics AG Switzerland Monte Rosa Therapeutics Securities Corp. Massachusetts |
|
| March 20, 2025 |
Form of Senior Indenture between Registrant and one or more trustees to be named Exhibit 4.5 MONTE ROSA THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Cert |
|
| March 20, 2025 |
Proteome Editing Through Molecular Glue Degraders Innovating Beyond New Heights | March 2025 Proteome Editing Through Molecular Glue Degraders Innovating Beyond New Heights | March 2025 Forward-Looking Statements This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| March 20, 2025 |
Exhibit 1.3 AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSM March 20, 2025 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 1 to the Open Market Sale AgreementSM (the “Amendment No. 1”) is entered into as of the date first written above by and between Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), and Jefferies LLC, as s |
|
| January 31, 2025 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated January 31, 2025 with respect to the Common Stock, $0.0001 par value per share, of Monte Rosa Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accord |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com |
|
| January 10, 2025 |
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025 Initial clinical data from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader (MGD) MRT-6160 expected in Q1 2025 Additional clinical results from Phase 1/2 study of MRT-2359 in MYC-driven solid tumors, including biomarker and activity data, anticipated in Q1 2025 MRT-8102, a NEK7-directed MGD targeting diseases driven by IL-1β and the NLRP3 inflammasome, on track for IND filing in H1 2025 Year-end cash and equivalents expected to be $377 million as of December 31, 2024 (unaudited) and anticipated to fund operations into 2028 through multiple anticipated proof-of-concept clinical readouts Company to present at J. |
|
| January 10, 2025 |
Proteome Editing Through Molecular Glue Degraders Innovating Beyond New Heights | January 2025 Proteome Editing Through Molecular Glue Degraders Innovating Beyond New Heights | January 2025 Forward-Looking Statements This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Co |
|
| December 5, 2024 |
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule in heavily pretreated solid tumor patients Recommended Phase 2 dose determined as 0. |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com |
|
| December 5, 2024 |
From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | December 2024 From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | December 2024 Forward-Looking Statements This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| November 7, 2024 |
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update Executed global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed molecular glue degraders including MRT-6160 for immune-related conditions; $150M upfront payment, eligible for up to $2. |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc. |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com |
|
| October 30, 2024 |
SC 13D/A 1 d886758dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERE TO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Secur |
|
| October 28, 2024 |
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders Agreement expected to accelerate MRT-6160 clinical development and broadly explore therapeutic opportunities across multiple indications Monte Rosa to receive up-front payment of $150 million and is eligible to receive milestone payments, U. |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com |
|
| September 24, 2024 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERE TO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61225M102 (CUSIP Number |
|
| August 12, 2024 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERE TO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61225M102 (CUSIP Number |
|
| August 12, 2024 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 61225M102 (CUSIP Number) Stephanie Brecher New Enterprise Associates 1954 Greenspring Drive, Suite 600 Timonium, MD 21093 |
|
| August 8, 2024 |
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update IND clearance achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; on track to initiate Phase 1 SAD/MAD study this summer with initial clinical data expected in Q1 2025 Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrated a favorable safety and pharmacodynamic profile at 0. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc. |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commi |
|
| August 8, 2024 |
Exhibit 10.1 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this “Agreement”) is made between Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), and Jennifer Champoux (the “Executive”) and is effective as of May 28, 2024 (the “Effective Date”). WHEREAS, the Company and the Executive are parties to prior Employment Agreements tha |
|
| June 27, 2024 |
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160 Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0. |
|
| June 27, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commis |
|
| June 12, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commis |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commiss |
|
| May 30, 2024 |
Monte Rosa Therapeutics Announces Leadership Team Promotions EX-99.1 Exhibit 99.1 Monte Rosa Therapeutics Announces Leadership Team Promotions BOSTON, Mass., May 30, 2024 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced three leadership team promotions effective immediately: Sharon Townson, Ph.D., to Chief Scientific Officer; Phil Nickson, P |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commiss |
|
| May 16, 2024 |
10,638,476 Shares of Common Stock Pre-funded Warrants to Purchase 10,638,524 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266003 Prospectus Supplement (To prospectus dated July 13, 2022) 10,638,476 Shares of Common Stock and Pre-funded Warrants to Purchase 10,638,524 Shares of Common Stock We are offering 10,638,476 shares of our common stock, par value $0.0001 per share, or the common stock, in this offering and, in lieu of common stock to certa |
|
| May 16, 2024 |
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering Exhibit 99.1 Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering BOSTON, Mass., May 16, 2024 – Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 10,638,476 shares of its common stock at |
|
| May 16, 2024 |
Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK MONTE ROSA THERAPEUTICS, INC. Number of Shares: [ ] (subject to adjustment) Warrant No. 2024-PF-0[ ] Original Issue Date: May [ ], 2024 Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ |
|
| May 16, 2024 |
Exhibit 1.1 Monte Rosa Therapeutics, Inc. 10,638,476 Shares of Common Stock And Pre-Funded Warrants to Purchase 10,638,524 Shares of Common Stock Underwriting Agreement May 15, 2024 TD Securities (USA) LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Monte Rosa Therapeutics, |
|
| May 15, 2024 |
Subject to Completion Preliminary Prospectus Supplement dated May 15, 2024 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266003 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these |
|
| May 13, 2024 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 61225M102 (CUSIP Number) Stephanie Brecher New Enterprise Associates 1954 Greenspring Drive, Suite 600 Timonium, MD 21093 |
|
| May 9, 2024 |
From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | May 2024 From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | May 2024 Forward-Looking Statements This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commissi |
|
| May 9, 2024 |
Exhibit 3.3 SECOND AMENDED AND RESTATED BYLAWS OF MONTE ROSA THERAPEUTICS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States that is fixed by or in the manner determined by the Board of |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc. |
|
| May 9, 2024 |
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; determination of recommended Phase 2 dose expected in Q2 2024; Phase 1 clinical data anticipated in H2 2024 MRT-6160, a VAV1-directed MGD in development for systemic |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commi |
|
| May 2, 2024 |
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer Dr. Wallace will depart his role as CSO effective May 17, 2024, and will serve as a scientific advisor, including on Monte Rosa’s Scientific Advisory Board BOSTON, Mass., May 2, 2024 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue d |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 14, 2024 |
Exhibit 4.2 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Monte Rosa Therapeutics, Inc. (the “Company,” “we,” or “our”) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Fo |
|
| March 14, 2024 |
Monte Rosa Therapeutics, Inc. Compensation Recovery Policy Exhibit 97.1 Monte Rosa Therapeutics, Inc. COMPENSATION RECOVERY POLICY Adopted as of September 27, 2023 Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Co |
|
| March 14, 2024 |
As filed with the Securities and Exchange Commission on March 14, 2024 As filed with the Securities and Exchange Commission on March 14, 2024 Registration No. |
|
| March 14, 2024 |
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; program on track with determination of recommended Phase 2 dose expected in Q2 2024 MRT-6160, a VAV1-directed MGD designed to treat systemic and neuro |
|
| March 14, 2024 |
List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Registrant Subsidiary Jurisdiction of Incorporation or Organization Monte Rosa Therapeutics AG Switzerland Monte Rosa Therapeutics Securities Corp. Massachusetts |
|
| March 14, 2024 |
Exhibit 107 Calculation of Registration Fee Form S-8 (Form Type) Monte Rosa Therapeutics, Inc. |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40522 Monte Rosa Ther |
|
| March 14, 2024 |
From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | March 2024 From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | March 2024 Forward-Looking Statements This communication includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commi |
|
| February 14, 2024 |
SC 13G/A 1 sc13ga.htm AMENDMENT NO. 3 CUSIP NO. 61225M102 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 61225M102 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check |
|
| February 14, 2024 |
GLUE / Monte Rosa Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13G Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
SC 13G/A 1 p24-0276sc13ga.htm MONTE ROSA THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61225M102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of Thi |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Comm |
|
| January 8, 2024 |
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024 Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors on track; recommended Phase 2 dose (RP2D) expected in Q2 2024 Received US FDA Fast Track Designation for MRT-2359 for previously treated, metastatic small cell lung cancer with L- or N-MYC expression MRT-6160, a VAV1-directed MGD, anticipated to initiate Phase 1 study in mid-2024, supporting potential future Phase 2 proof-of-concept studies in multiple autoimmune diseases Strong cash position expected to fund operations into H1 2026 and enable advancement of pipeline programs through significant early clinical milestones Company to present at J. |
|
| January 8, 2024 |
From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | January 2024 From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | January 2024 Forward-Looking Statements These materials include express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc. |
|
| November 9, 2023 |
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update Interim data from Phase 1/2 clinical trial of MRT-2359 demonstrated tumor reductions in patients with biomarker-positive cancers; recommended Phase 2 dose expected in Q2 2024 Announced strategic collaboration with Roche to discover novel molecular glue degraders targeting cancer and neurological di |
|
| November 9, 2023 |
GLUE / Monte Rosa Therapeutics Inc / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d494819dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERE TO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Secur |
|
| November 9, 2023 |
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| October 26, 2023 |
Pre-funded warrants to purchase 10,000,400 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266003 Prospectus Supplement (To prospectus dated July 13, 2022) Pre-funded warrants to purchase 10,000,400 Shares of Common Stock We are offering pre-funded warrants to purchase 10,000,400 shares of our common stock, in a registered direct offering to a limited number of purchasers pursuant to this prospectus supplement |
|
| October 26, 2023 |
Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK MONTE ROSA THERAPEUTICS, INC. Number of Shares: [ ] (subject to adjustment) Warrant No. 2023-PF-0[ ] Original Issue Date: October [ ], 2023 Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledg |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com |
|
| October 26, 2023 |
Exhibit 99.1 Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules BOSTON, Mass., October 26, 2023 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has raised $25 million at-the-market from a life sciences-dedicat |
|
| October 26, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of October 26, 2023, by and among Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS A. The Investors wish to purchase from the Compa |
|
| October 17, 2023 |
From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | October 2023 From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | October 2023 Forward-Looking Statements These materials include express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| October 17, 2023 |
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors Optimal levels of degradation of GSPT1 in peripheral blood mononuclear cells and tumors observed at all doses, consistent with preclinical studies Tumor size reductions observed in patients with biomarker-positive tumors Safety profile supports further clinical development of MRT-2359 Conference call and webcast at 8:00 a. |
|
| October 17, 2023 |
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases Collaboration combines Monte Rosa Therapeutics’ highly differentiated QuEENTM discovery engine with Roche’s strong expertise in delivering transformative therapies to patients Monte Rosa to receive an upfront payment of $50 million and potential future payments exceeding $2 billion BOSTON, Mass. |
|
| October 17, 2023 |
From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | October 2023 From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | October 2023 Forward-Looking Statements These materials include express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| October 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com |
|
| August 10, 2023 |
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update ● On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors in the second half of 2023 ● Received Orphan Drug Designation from the U. |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc. |
|
| August 10, 2023 |
Separation Agreement between the Registrant and Ajim Tamboli, effective as of August 8, 2023. Exhibit 10.1 August 9, 2023 PERSONAL AND CONFIDENTIAL Ajim Tamboli, CFA Re: Separation Agreement Dear Ajim: This letter will confirm your resignation from Monte Rosa Therapeutics, Inc. (the “Company”) effective August 8, 2023 (the “Separation Date”). This letter also sets forth the terms of a separation agreement between you and the Company (the “Agreement”) that would provide you with severance p |
|
| August 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Comm |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commis |
|
| June 14, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MONTE ROSA THERAPEUTICS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Monte Rosa Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The Corporation was ori |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commis |
|
| May 11, 2023 |
Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update • On track to present initial data from Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors in the second half of 2023 • Cash runway into 2025 supports operations and advancement of pipeline of novel molecular glue degraders to key inflection points BOSTON, Mass. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commiss |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc. |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commi |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40522 Monte Rosa Ther |
|
| March 16, 2023 |
From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | March 2023 From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | March 2023 Forward-Looking Statements These materials include express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| March 16, 2023 |
List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Registrant Subsidiary Jurisdiction of Incorporation or Organization Monte Rosa Therapeutics AG Switzerland Monte Rosa Therapeutics Securities Corp. Massachusetts |
|
| March 16, 2023 |
As filed with the Securities and Exchange Commission on March 16, 2023 As filed with the Securities and Exchange Commission on March 16, 2023 Registration No. |
|
| March 16, 2023 |
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update • Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoing • Disclosure of initial data from Phase 1 arm of study expected in second half of 2023 • MRT-2359 received Fast Track designation from FDA for treatment of patients with previously treated, metastatic non-small cell lung cancer (NSCLC) with L-MYC or N-MYC expression • Nomination of multiple development candidates anticipated in 2023 • Year-end 2022 cash balance of approximately $268 million, with cash runway into 2025 BOSTON, March 16, 2023 – Monte Rosa Therapeutics, Inc. |
|
| March 16, 2023 |
Exhibit 107 Calculation of Registration Fee Form S-8 (Form Type) Monte Rosa Therapeutics, Inc. |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commi |
|
| February 14, 2023 |
GLUE / Monte Rosa Therapeutics, Inc. / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 sc13g.htm CUSIP NO. 61225M102 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 61225M102 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate b |
|
| February 14, 2023 |
SC 13G/A 1 p23-0270sc13ga.htm MONTE ROSA THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61225M102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of Thi |
|
| January 9, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Comm |
|
| January 9, 2023 |
From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | January 2023 From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | January 2023 Forward-Looking Statements These materials include express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| January 9, 2023 |
EX-99.2 3 glue-ex992.htm EX-99.2 Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023 • MRT-2359 received Fast Track designation from the FDA for the treatment of patients with previously treated, metastatic non-small cell lung cancer (NSCLC) with L-MYC or N-MYC expression • Disclosure of initial data from Phase 1 arm of ong |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Co |
|
| November 10, 2022 |
Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates ? Initiated Patient Dosing in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors ? ? Progressed VAV1 Molecular Glue Degrader Program into Lead Optimization ? BOSTON, November 10, 2022 ? Monte Rosa Therapeutics, Inc. |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc. |
|
| October 24, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2022 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com |
|
| October 24, 2022 |
Exhibit 99.1 MRT-2359 KOL Webinar hosted by Cowen October 24, 2022 Guest Speakers Jordi Rodon Ahnert, M.D., Ph.D., Department of Investigational Cancer Therapeutics, Division of Cancer Medicine at MD Anderson Cancer Center Davide Ruggero, Ph.D., Professor, Department of Urology and Cellular & Molecular Pharmacology at UCSF; Helen Diller Family Endowed Chair in Basic Cancer Research Forward-Looking |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Comm |
|
| August 11, 2022 |
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates ? Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid Tumors ? ? Cash Runway into Late 2024 with $299. |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc. |
|
| July 11, 2022 |
July 11, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 1, 2022 |
As filed with the Securities and Exchange Commission on July 1, 2022 Table of Contents As filed with the Securities and Exchange Commission on July 1, 2022 Registration No. |
|
| July 1, 2022 |
Form of Senior Indenture between Registrant and one or more trustees to be named Exhibit 4.5 MONTE ROSA THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s |
|
| July 1, 2022 |
Open Market Sale AgreementSM, dated as of July 1, 2022, between the Registrant and Jefferies LLC Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM July 1, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Monte Rosa Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s comm |
|
| July 1, 2022 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named Exhibit 4.6 MONTE ROSA THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities TABLE OF CONTENTS1 Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s |
|
| July 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Monte Rosa Therapeutics, Inc. |
|
| June 15, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commis |
|
| June 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| May 11, 2022 |
Exhibit 10.2 AGREEMENT FOR TERMINATION OF LEASE This AGREEMENT FOR TERMINATION OF LEASE (this ?Agreement?) is entered into as of this 5th day of May, 2022 (the ?Effective Date?), by and between OPG MP PARCEL OWNER (DE) LLC, a Delaware limited liability company (?Landlord?), and MONTE ROSA THERAPEUTICS, INC., a Delaware corporation (?Tenant?). Recitals A. Landlord is the owner of certain real prope |
|
| May 11, 2022 |
Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates ? Presented Preclinical Data at AACR Annual Meeting Supporting Clinical Development of MRT-2359 as Potent and Selective GSPT1-directed Molecular Glue Degrader in Solid Tumors; Company on Track to File Investigational New Drug (IND) Application Mid-year ? ? Initiated Research with ?cole Polytechnique F?d?rale de Lausanne (EPFL); Collaboration to Broaden Monte Rosa?s AI Capabilities ? BOSTON, May 11, 2022 ? Monte Rosa Therapeutics, Inc. |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commiss |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc. |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 29, 2022 |
Exhibit 10.22 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this ?Agreement?) is made between Monte Rosa Therapeutics, Inc., a Delaware corporation (the ?Company?), and Philip Nickson, JD, Ph.D. (the ?Executive?) and is effective as of March 1, 2022 (the ?Effective Date?). WHEREAS, the Company and the Executive are parties to an Employment Agreement that |
|
| March 29, 2022 |
Exhibit 4.2 Description of the Registrant?s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Monte Rosa Therapeutics, Inc. (the ?Company,? ?we,? or ?our?) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Fo |
|
| March 29, 2022 |
Exhibit 10.21 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made between Monte Rosa Therapeutics, Inc., a Delaware corporation (the ?Company?), and Jullian Jones, Ph.D., J.D., MBA (the ?Executive?) and is effective as of the closing of the Company?s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securitie |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40522 Monte Rosa Ther |
|
| March 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commi |
|
| March 29, 2022 |
Exhibit 10.20 LEASE by and between B9 LS HARRISON & WASHINGTON LLC, a Delaware limited liability company and MONTE ROSA THERAPEUTICS, INC., a Delaware corporation Table of Contents 1. Lease of Premises 1 2. Basic Lease Provisions 2 3. Term 5 4. Possession and Commencement Date. 6 5. Condition of Premises 8 6. Rentable Area 8 7. Rent 9 8. Rent Adjustments 10 9. Operating Expenses 10 10. Taxes on Te |
|
| March 29, 2022 |
As filed with the Securities and Exchange Commission on March 29, 2022 As filed with the Securities and Exchange Commission on March 29, 2022 Registration No. |
|
| March 29, 2022 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Monte Rosa Therapeutics, Inc. |
|
| March 29, 2022 |
Exhibit 99.1 Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates ? Company on Track for Mid-year Filing of Investigational New Drug (IND) Application for Lead Candidate MRT-2359 ? ? Progressed NEK7 and CDK2 Molecular Glue Degrader Programs into Lead Optimization ? ? Year-end Cash and Cash Equivalents Expected to Provide Runway into Late 2024 ? B |
|
| March 29, 2022 |
List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of Registrant Subsidiary Jurisdiction of Incorporation or Organization Monte Rosa Therapeutics AG Switzerland Monte Rosa Therapeutics Securities Corp. Massachusetts |
|
| February 14, 2022 |
GLUE / Monte Rosa Therapeutics, Inc. / Cormorant Asset Management, LP Passive Investment CUSIP NO. 61225M102 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 61225M102 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 11, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61225M102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pu |
|
| January 10, 2022 |
From Serendipity to Rational Design Taking Molecular Glue Degraders to New Heights | January 2022 Exhibit 99. |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Com |
|
| December 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Co |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Co |
|
| November 12, 2021 |
Exhibit 99.1 Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Business Updates ? Initiated Investigational New Drug (IND)-Enabling Activities for MRT-2359, a Molecular Glue Degrader Selectively Targeting GSPT1 ? ? Presented Preclinical Data at AACR-NCI-EORTC Highlighting the Potential of GSPT1-directed Molecular Glue Degraders for t |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc. |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Comm |
|
| August 12, 2021 |
Exhibit 99.1 Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress ? Completed upsized $255.6 million IPO; cash runway extended into late 2024 ? Continued advancement of QuEENTM protein degradation platform and pipeline of molecular glue degraders, including NEK7 program ? BOSTON, August 12, 2021 ? Monte Rosa Therapeutics, Inc. (NASDAQ: |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc. |
|
| July 12, 2021 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 6122JM102 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 2 |
|
| July 8, 2021 |
GLUE / Monte Rosa Therapeutics, Inc. / Versant Venture Capital VI, L.P. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERE TO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61225M102 (CUSIP Number) V |
|
| July 8, 2021 |
GLUE / Monte Rosa Therapeutics, Inc. / Cormorant Asset Management, LP Passive Investment CUSIP NO. 61225M102 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 61225M102 (CUSIP Number) June 28, 2021† (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| July 8, 2021 |
Exhibit 3 FORM OF LOCK-UP AGREEMENT June 19, 2021 J.P. MORGAN SECURITIES LLC COWEN AND COMPANY, LLC PIPER SANDLER & CO. As Representatives of the several Underwriters listed in Schedule 1 to the Underwriting Agreement referred to below c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o Cowen and Company, LLC 599 Lexington Avenue, 25th Floor New York, NY 1022 c/o Piper Sandler |
|
| July 8, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of July 8, 2021, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare GP II, LLC, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare GP III, LLC, Cormorant Asset Management, LP and Bihua Ch |
|
| July 8, 2021 |
Exhibit 1 Joint Filing Agreement The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Monte Rosa Therapeutics, Inc. |
|
| June 28, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF MONTE ROSA THERAPEUTICS, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and pla |
|
| June 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2021 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40522 84-3766197 (State or other jurisdiction of incorporation) (Commis |
|
| June 28, 2021 |
Exhibit 3.1 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MONTE ROSA THERAPEUTICS, INC. Monte Rosa Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Monte Rosa Therapeutics, Inc. The date of the filing of its original Certificate of Incorporation with the |
|
| June 25, 2021 |
Exhibit 99.2 MONTE ROSA THERAPEUTICS, INC. 2021 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Monte Rosa Therapeutics, Inc. 2021 Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Monte Rosa Therapeutics, Inc. (the ?Compa |
|
| June 25, 2021 |
Overview of protein degradation 424B4 1 d47776d424b4.htm 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Statement No. 333-256773 Prospectus 11,700,000 Shares Common stock This is an initial public offering of shares of common stock by Monte Rosa Therapeutics, Inc. We are offering 11,700,000 shares of common stock. The initial public offering price is $19.00 per share. Prior to this offering, there has been |
|
| June 25, 2021 |
As filed with the Securities and Exchange Commission on June 25, 2021 Registration No. |
|
| June 23, 2021 |
As filed with the Securities and Exchange Commission on June 23, 2021. As filed with the Securities and Exchange Commission on June 23, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Monte Rosa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 81-3766197 (State or other jurisdiction of (Primary Standard Industrial |
|
| June 21, 2021 |
Exhibit 10.8 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made between Monte Rosa Therapeutics, Inc., a Delaware corporation (the ?Company?), and Ajim Tamboli, CFA (the ?Executive?) and is effective as of the closing of the Company?s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 MONTE ROSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 84-3766197 (State of incorporation or organization) (I.R.S. Employer Identification No.) 645 Summer Str |
|
| June 21, 2021 |
Exhibit 10.2 MONTE ROSA THERAPEUTICS, INC. 2021 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Monte Rosa Therapeutics, Inc. 2021 Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Monte Rosa Therapeutics, Inc. (the ?Compa |
|
| June 21, 2021 |
Exhibit 4.2 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $0.0001 COMMON STOCK Monte Rosa THERAPEUTICS Certificate Number ZQ00000000 MONTE ROSA THERAPEUTICS, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS CERTIFIES THAT is the owner of MR. SAMPLE & MRS. SAMPLE & MR. SAMPLE & MRS. SAMPLE ***ZERO HUNDRED THOUSAND ZERO HUNDRED AND ZERO*** Shares * * 000000 |
|
| June 21, 2021 |
Exhibit 10.10 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made between Monte Rosa Therapeutics, Inc., a Delaware corporation (the ?Company?), and Sharon Townson, Ph.D. (the ?Executive?) and is effective as of the closing of the Company?s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1 |
|
| June 21, 2021 |
Exhibit 10.3 MONTE ROSA THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Monte Rosa Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the ?Plan?) is to provide eligible employees of Monte Rosa Therapeutics, Inc. (the ?Company?) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company?s common stock, par value $0.0001 |
|
| June 21, 2021 |
Exhibit 10.7 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made between Monte Rosa Therapeutics, Inc., a Delaware corporation (the ?Company?), and Markus Warmuth, M.D. (the ?Executive?) and is effective as of the closing of the Company?s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 193 |
|
| June 21, 2021 |
[Remainder of page left intentionally blank] CORRESP 1 filename1.htm VIA EDGAR June 21, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attn: Kasey Robinson Jeffrey Gabor Re: Monte Rosa Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-256773 Requested Date: June 23, 2021 Requested Time: 4:00 p.m. Eastern Standard T |
|
| June 21, 2021 |
Form of Underwriting Agreement Exhibit 1.1 Monte Rosa Therapeutics, Inc. [?] Shares of Common Stock Underwriting Agreement [?], 2021 J.P. Morgan Securities LLC Cowen and Company, LLC Piper Sandler & Co. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LLC 599 Lexington Avenue, 25th Floor New York, NY 1022 |
|
| June 21, 2021 |
Exhibit 10.9 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made between Monte Rosa Therapeutics, Inc., a Delaware corporation (the ?Company?), and Owen Wallace, Ph.D. (the ?Executive?) and is effective as of the closing of the Company?s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933 |
|
| June 21, 2021 |
CORRESP 1 filename1.htm VIA EDGAR June 21, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attn: Kasey Robinson Jeffrey Gabor Re: Monte Rosa Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-256773 Requested Date: June 23, 2021 Requested Time: 4:00 p.m. Eastern Time Dear |
|
| June 21, 2021 |
Exhibit 10.12 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made between Monte Rosa Therapeutics, Inc., a Delaware corporation (the ?Company?), and Filip Janku, MD, PhD (the ?Executive?) and is effective as of the closing of the Company?s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 19 |
|
| June 21, 2021 |
Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 June 21, 2021 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attention: Kasey Robinson and Jeffrey Gabor Re: Monte Rosa Therapeutics, Inc. Amendment No. 1 to Registration Statement on Form S- |
|
| June 21, 2021 |
Exhibit 10.11 Employment Agreement Dated as of 17 June, 2021 by and between Monte Rosa Therapeutics AG (the Company) Aeschenvorstadt 36, 4051 Basel, Switzerland and Dr. John Castle (the Executive) Rudolf-Diesel-Strasse 40, 55131 Mainz, Germany (The Company and the Executive are also referred to as Party or Parties) 1 of 15 Employment Agreement Employment Agreement Preamble A. The Executive and the |
|
| June 21, 2021 |
Form S-1, as amended (File No. 333-256773) Table of Contents As filed with the Securities and Exchange Commission on June 21, 2021 Registration No. |
|
| June 11, 2021 |
CONFIDENTIAL TREATMENT REQUESTED BY MONTE ROSA THERAPEUTICS, INC. FOIA CONFIDENTIAL TREATMENT REQUEST The entity requesting confidential treatment is Monte Rosa Therapeutics, Inc. |
|
| June 9, 2021 |
CORRESP 1 filename1.htm Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 June 9, 2021 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attention: Kasey Robinson and Jeffrey Gabor Re: Monte Rosa Therapeutics, Inc. Draft Registration Statement |
|
| June 9, 2021 |
As filed with the Securities and Exchange Commission on June 9, 2021 S-1/A 1 d47776ds1a.htm S-1/A Table of Contents As filed with the Securities and Exchange Commission on June 9, 2021 Registration No. 333–256773 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Monte Rosa Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 8 |
|
| June 4, 2021 |
Exhibit 10.6 MONTE ROSA THERAPEUTICS, INC. [FORM OF] DIRECTOR INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of [Date] by and between Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), and [Director Name] (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee |
|
| June 4, 2021 |
Exhibit 10.14 CONTRIBUTION AND EXCHANGE AGREEMENT THIS CONTRIBUTION AND EXCHANGE AGREEMENT (the ?Agreement?) is made effective as of the 1st day of September, 2020 (the ?Contribution Date?) by and among the undersigned Shareholders (the ?Shareholders?) of record of Monte Rosa Therapeutics AG, a company incorporated in Switzerland, having its registered office at Aeschenvorstadt 36, 4051 Basel, Swi |
|
| June 4, 2021 |
Exhibit 3.2 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MONTE ROSA THERAPEUTICS, INC. Monte Rosa Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Monte Rosa Therapeutics, Inc. The date of the filing of its original Certificate of Incorporation with the |
|
| June 4, 2021 |
Lease Agreement, dated September 23, 2020, between OPG MP Parcel Owner (DE) LLC and the Registrant EX-10.19 18 d47776dex1019.htm EX-10.19 Exhibit 10.19 645 SUMMER STREET BOSTON, MA LEASE AGREEMENT BETWEEN OPG MP PARCEL OWNER (DE) LLC, a Delaware limited liability company, AS LANDLORD AND MONTE ROSA THERAPEUTICS, INC., a Delaware corporation, AS TENANT LEASE AGREEMENT TABLE OF CONTENTS 1. Basic Lease Information 1 2. Lease Grant 3 3. Term and Commencement Date 4 4. Rent 5 5. Compliance with Laws |
|
| June 4, 2021 |
EX-10.15 14 d47776dex1015.htm EX-10.15 Exhibit 10.15 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. SERVICES AGREEMENT THIS SERVICES AGREEMENT (this “Agreement”), ef |
|
| June 4, 2021 |
EX-10.13 12 d47776dex1013.htm EX-10.13 Exhibit 10.13 CONTRIBUTION AND EXCHANGE AGREEMENT THIS CONTRIBUTION AND EXCHANGE AGREEMENT (THE “AGREEMENT”) IS MADE EFFECTIVE AS OF THE 14th DAY OF APRIL, 2020 (THE “CONTRIBUTION DATE”) BY AND AMONG THE UNDERSIGNED SHAREHOLDERS (THE “SHAREHOLDERS”) OF RECORD OF MONTE ROSA THERAPEUTICS AG, A COMPANY INCORPORATED IN SWITZERLAND, HAVING ITS REGISTERED OFFICE AT |
|
| June 4, 2021 |
Form of Officer Indemnification Agreement Exhibit 10.5 MONTE ROSA THERAPEUTICS, INC. [FORM OF] OFFICER INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of [Date] by and between Monte Rosa Therapeutics, Inc., a Delaware corporation (the ?Company?), and [Officer Name] (?Indemnitee?). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, |
|
| June 4, 2021 |
Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MONTE ROSA THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Monte Rosa Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”). DOES HEREBY C |
|
| June 4, 2021 |
Senior Executive Cash Incentive Bonus Plan EX-10.4 9 d47776dex104.htm EX-10.4 Exhibit 10.4 MONTE ROSA THERAPEUTICS, INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the “Incentive Plan”) is intended to provide an incentive for superior work and to motivate eligible executives of Monte Rosa Therapeutics, Inc. (the “Company”) and its subsidiaries toward even higher achievement and bu |
|
| June 4, 2021 |
Exhibit 4.2 . ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK COMMON STOCK PO PAR VALUE $0.0001 MR ADD ADD ADD ADD 4 3 2 1 A BOX DESIGNATION SAMPLE Certificate Shares 505006, Number 000000 (IF 000000 ANY) ZQ00000000 000000 Louisville, MONTE ROSA THERAPEUTICS, INC. 000000 KY 000000 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE Mr. Alexander David Sample Mr. Alexander David S |
|
| June 4, 2021 |
By-laws of the Registrant, as currently in effect Exhibit 3.3 BY-LAWS of MONTE ROSA THERAPEUTICS, INC. (the ?Corporation?) 1. Stockholders (a) Annual Meeting. The annual meeting of stockholders shall be held for the election of directors each year at such place, date and time as shall be designated by the Board of Directors. Any other proper business may be transacted at the annual meeting. If no date for the annual meeting is established or said |
|
| June 4, 2021 |
Exhibit 3.4 AMENDED AND RESTATED BY-LAWS OF MONTE ROSA THERAPEUTICS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and pla |
|
| June 4, 2021 |
Power of Attorney (included on signature page to this registration statement) Table of Contents As filed with the Securities and Exchange Commission on June 4, 2021 Registration No. |
|
| June 4, 2021 |
2020 Stock Option and Grant Plan, as amended, and forms of award agreements thereunder Exhibit 10.1 MONTE ROSA THERAPEUTICS, INC. 2020 STOCK OPTION AND GRANT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Monte Rosa Therapeutics, Inc. Stock Option and Grant Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key persons of Monte Rosa Therapeutics, Inc., a Delaware corpor |
|
| June 4, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries Subsidiary Jurisdiction of Incorporation or Organization Monte Rosa Therapeutics AG Switzerland Monte Rosa Therapeutics Securities Corp. Massachusetts |
|
| June 4, 2021 |
Exhibit 4.1 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 11th day of March, 2021, by and among Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.” RECITALS |
|
| June 4, 2021 |
Exhibit 10.17 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. Annex 2.7: Background IP License Agreement [separate Document] LICENSE AGREEMENT (1) CANCER RESEARCH TEC |
|
| June 4, 2021 |
Exhibit 10.18 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. COLLABORATION AND OPTION AGREEMENT (1) CANCER RESEARCH TECHNOLOGY LIMITED AND (2) THE INSTITUTE OF CANCE |
|
| June 4, 2021 |
Exhibit 10.16 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. SERVICES AGREEMENT THIS SERVICES AGREEMENT (the “Agreement”) is made as of December 29, 2020, by and bet |
|
| May 21, 2021 |
DRSLTR 1 filename1.htm Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 May 21, 2021 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attention: Kasey Robinson and Jeffrey Gabor Re: Monte Rosa Therapeutics, Inc. Draft Registration Statement o |
|
| May 21, 2021 |
DRS/A 1 filename1.htm Table of Contents As confidentially submitted to the Securities and Exchange Commission on May 21, 2021 as Amendment No. 2 to the draft registration statement submitted on April 19, 2021. This Amendment No. 2 to the draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains confidential. Registration |
|
| April 30, 2021 |
EX-10.14 2 filename2.htm Exhibit 10.14 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. SERVICES AGREEMENT THIS SERVICES AGREEMENT (this “Agreement”), effective as of |
|
| April 30, 2021 |
As confidentially submitted to the Securities and Exchange Commission on April 30, 2021 as Amendment No. |
|
| April 30, 2021 |
EX-10.15 3 filename3.htm Exhibit 10.15 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. SERVICES AGREEMENT THIS SERVICES AGREEMENT (the “Agreement”) is made as of Dece |
|
| April 30, 2021 |
Exhibit 10.16 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. Annex 2.7: Background IP License Agreement [separate Document] LICENSE AGREEMENT (1) CANCER RESEARCH TEC |
|
| April 30, 2021 |
EX-10.17 5 filename5.htm Exhibit 10.17 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. COLLABORATION AND OPTION AGREEMENT (1) CANCER RESEARCH TECHNOLOGY LIMITED AND ( |
|
| April 19, 2021 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on April 19, 2021. |
|
| April 19, 2021 |
EX-10.18 6 filename6.htm Exhibit 10.18 645 SUMMER STREET BOSTON, MA LEASE AGREEMENT BETWEEN OPG MP PARCEL OWNER (DE) LLC, a Delaware limited liability company, AS LANDLORD AND MONTE ROSA THERAPEUTICS, INC., a Delaware corporation, AS TENANT LEASE AGREEMENT TABLE OF CONTENTS 1. Basic Lease Information 1 2. Lease Grant 3 3. Term and Commencement Date 4 4. Rent 5 5. Compliance with Laws; Use 6 6. Let |
|
| April 19, 2021 |
EX-3.1 2 filename2.htm Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MONTE ROSA THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Monte Rosa Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporati |
|
| April 19, 2021 |
EX-21.1 7 filename7.htm Exhibit 21.1 Subsidiaries Subsidiary Jurisdiction of Incorporation or Organization Monte Rosa Therapeutics AG Switzerland Monte Rosa Therapeutics Securities Corp. Massachusetts |
|
| April 19, 2021 |
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT EX-4.1 4 filename4.htm Exhibit 4.1 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 11th day of March, 2021, by and among Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as |
|
| April 19, 2021 |
MONTE ROSA THERAPEUTICS, INC. 2020 STOCK OPTION AND GRANT PLAN EX-10.1 5 filename5.htm Exhibit 10.1 MONTE ROSA THERAPEUTICS, INC. 2020 STOCK OPTION AND GRANT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Monte Rosa Therapeutics, Inc. Stock Option and Grant Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key persons of Monte Rosa Therapeutics, |
|
| April 19, 2021 |
BY-LAWS MONTE ROSA THERAPEUTICS, INC. (the “Corporation”) EX-3.3 3 filename3.htm Exhibit 3.3 BY-LAWS of MONTE ROSA THERAPEUTICS, INC. (the “Corporation”) 1. Stockholders (a) Annual Meeting. The annual meeting of stockholders shall be held for the election of directors each year at such place, date and time as shall be designated by the Board of Directors. Any other proper business may be transacted at the annual meeting. If no date for the annual meeting |
